Latest news
25 items- PRBiophytis Publishes First-Half Financial Results and Provides an Update on its Business ActivitiesPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (PARIS:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing treatments for age-related diseases, publishes today its financial results for the first half of 2024 and provides an update on the company's key achievements.Stanislas Veillet, CEO of Biophytis, commented:"We are particularly pleased with the progress made in the first half of 2024. The launch of our clinical program OBA for obesity, addressing a major public health issue, and our partnership with Blanver to develop BIO101 in Latin America, are key milestones that demonstrate Biophytis' ability to innovate
- PRBiophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in AsiaPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia.To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.This initiative is
- PRBiophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in ObesityPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone).The primary objective of the study is to measure the improvement in muscle strength in the lower limbs, as assessed by knee extension test. Secondary endpoints will include analysis of mobility (via the 6-minute walk test) and body composition (assessment of fat an
- PRBiophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in ParisPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious Diseases department at Pitié Salpetriere, presented the COVAphase 2/3 clincial study results in a context where the number of Covid cases rises again. Dr. Claudia Fer
- PRBiophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 MillionBiophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the productAgreement covers commercialization of BIO101 in Latin AmericaBiophytis and Blanver intend to collaborate on manufacturing and joint clinical development for Latin America PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 20, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in B
- PRBiophytis Extends Its Contract With Atlas to Secure Financing for Its Business ActivitiesImportant note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting from the conversion or exercise of these instruments, is not intended to remain a shareholder of the company. The shares resulting from the conversion of the above-mentioned securities will, in general, be sold on the market very quickly, which may create downward pressure on the share price. Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company's stock, as well as significant dilution due to the large number of securities issued to t
- PRBiophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider SeqensPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the successful transfer of BIO101 (20-hydroxyecdysone) production to industrial scale by Seqens.Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in Villeneuve La Garenne (Île-de-France). This batch is
- PRBiophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in ObesityPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone).The OBA study will assess the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight patients with secondary comorbidities, treated for 21 weeks with GLP-1 receptor agonists (GLP-1 RAs) and undergoing hypocalori
- PRCombined General Meeting of June 24, 2024PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development oftherapeutics for age-related diseases, will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales Obligatoires (BALO) no. 59 of May 15, 2024.Information and preparatory documents for this General Meeting, including the voting form and the access map, are available on t
- SECSEC Form 6-K filed by Biophytis SA6-K - Biophytis SA (0001768946) (Filer)
- PRBiophytis Announces the Design of its Phase 2 OBA Clinical Study in ObesityPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone).BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss.Stanislas Veillet, CEO
- SECSEC Form 6-K filed by Biophytis SA6-K - Biophytis SA (0001768946) (Filer)
- NEWSBiophytis Is Deploying Its Partnership Strategy In ObesityBiophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a dedicated strategy for partner search in obesity.Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential to transform the lives of obese patients worldwide.Biophytis' partnering strategy is based on the search for the best partners selected through precise targeting and an in-depth analysis and understanding of th
- PRBiophytis is Deploying its Partnership Strategy in ObesityPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a dedicated strategy for partner search in obesity.Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential to transform the lives of obese patients worldwide.Biophytis' partnering strategy is based on the search for the best partners selected through pr
- NEWSWhy Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates. Caterpillar reported a first-quarter fiscal 2024 revenue of $15.8 billion, a slight decrease of 0.4% year-over-year, missing the consensus of $16.216 billion. CAT's adjusted earnings of $5.60 per share, compared to $4.91 a year ago, topped the consensus of $5.14, according to data from Benzinga Pro. Caterpillar shares dipped 6.6% to $339.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Barfresh Food Group, Inc. (NASDAQ:BRFH) surged 87.2% to $2.05. Safe & Green Holdin
- SECSEC Form 6-K filed by Biophytis SA6-K - Biophytis SA (0001768946) (Filer)
- NEWSWhy Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving PremarketShares of Teradyne, Inc. (NASDAQ:TER) rose sharply in today's pre-market trading after the company posted upbeat first-quarter results and issued strong second-quarter forecast. Teradyne posted adjusted earnings of 51 cents per share, beating market estimates of 33 cents per share. The company's quarterly sales came in at $599.819 million versus expectations of $566.310 million, according to data from Benzinga Pro. Teradyne shares jumped 8.4% to $109.20 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Intelligent Living Application Group Inc. (NASDAQ:ILAG) shares gained 57.3% to $0.8496 in pre-market trading after gaining over 12% on Wed
- PRBiophytis Announces Transfer of ADSs to OTC MarketADSs delisted from Nasdaq, which will result in meaningful savingsADSs transferred to OTC Pink market; Company will apply to trade on OTCQB marketBiophytis remains listed on Euronext Growth Paris as its primary trading marketPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 24, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related diseases, today announced that on April 24, 2024, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's American Depositary Shares("ADSs") fr
- NEWSBiophytis shares are trading lower after the company announced that it will change the ratio of its American Depositary Shares From 100 to 4,000.
- SECSEC Form 6-K filed by Biophytis SA6-K - Biophytis SA (0001768946) (Filer)
- NEWSBiophytis Announces ADR Ratio Change: From 100 To 4,000 Shares Per ADS, Effective April 23Biophytis SA (Nasdaq CM:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio of its American Depositary Shares (the "ADSs") to Biophytis ordinary shares (the "Shares") from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the "Ratio Change"). The effective date of the Ratio Change (the "Effective Date") is expected to be April 23, 2024.
- PRBiophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") ProgramPARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio of its American Depositary Shares (the "ADSs") to Biophytis ordinary shares (the "Shares") from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the "Ratio Change"). The effective date of the Ratio Change (the "Effective Date") is expected to be April 23, 2024.Pursuant to the Ratio Change, as of the Effective Date, record holders who directly hold ADRs will be required to exchange
- NEWSBiophytis shares are trading higher. The company announced the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity.
- SECSEC Form 6-K filed by Biophytis SA6-K - Biophytis SA (0001768946) (Filer)
- NEWSBiophytis Plans To File IND With FDA For Phase 2 OBA Clinical Study In Obesity, Backed By New Scientific Advisory BoardIND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be composed of a few worldwide medical experts in the field of obesity, including Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain. The OBA SAB will guide the company to develop BIO101 (20-hyd
BPTS FAQ
7 questionsWhat does Biophytis SA do?
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally...Where does BPTS stock trade?
Biophytis SA (BPTS) is listed on NASDAQ.What sector and industry is BPTS in?
Biophytis SA operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biophytis SA go public?
Biophytis SA (BPTS) completed its IPO in 2021.What are analysts saying about BPTS?
Biophytis SA has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $1500.00 price target on 2021-10-25. Recent price targets cluster around $1500.00.What companies are similar to BPTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BPTS side-by-side with any of them on Quantisnow.How can I track BPTS on Quantisnow?
Quantisnow aggregates Biophytis SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BPTS to receive live email and push alerts on every new disclosure.